Skip to main content

Table 3 Meta-analysis of relationships between mTOR/p-mTOR expression and clinicopathological characteristics of ESCC

From: Clinicopathological and prognostic significance of mTOR and phosphorylated mTOR expression in patients with esophageal squamous cell carcinoma: a systematic review and meta-analysis

Clinicopathological characteristics N No. samples Heterogeneity (I2, p) Model OR with 95 % CI P value Publication bias Conclusion
Total PE NE Begg (p) Egger (p)
Differentiation (G3 vs G1/G2) 6 568 285 283 I2 = 29.3 %, p = 0.216 Fixed 2.634 (1.714–4.047) 0.001 0.283 0.456 Significant
Depth of tumor invasion (T3/T4 vs T1/T2) 6 568 318 250 I2 = 0.0 %, p = 0.546 Fixed 1.477 (1.024–2.132) 0.037 0.452 0.355 Significant
TNM stage (III/IV vs I/II) 7 776 385 391 I2 = 82.9 %, p < 0.001 Random 2.248 (1.048–4.823) 0.037 0.087 0.216 Significant
Lymph node metastasis (Yes vs No) 8 838 418 420 I2 = 69.2 %, p = 0.002 Random 1.816 (1.062–3.105) 0.029 0.754 0.626 Significant
Gender (Male vs Female) 6 741 363 378 I2 = 0.0 %, p = 0.447 Fixed 0.811 (0.500–1.316) 0.396 0.371 0.273 Not significant
  1. CI confidence interval, ESCC esophageal squamous cell carcinoma, mTOR Mammalian Target of Rapamycin, N reference count, NE negative expression, OR odds ratio, PE positive expression, p-mTOR Phosphorylated Mammalian Target of Rapamycin